Hemogenyx Pharmaceuticals Share Surge Continues as 3rd Patient Successfully Treated in Trial of HG-CT-1

Hemogenyx Pharmaceuticals shares climbed more than 21% on Wednesday after the company announced that a third patient has been successfully treated in the Phase I trial of its experimental CAR-T therapy for acute myeloid leukaemia (AML).

The London-listed biotech said the treatment was well tolerated and met the trial’s initial safety criteria. Early signs of efficacy were also observed, with preliminary testing showing no detectable AML cells in the patient following therapy.

The Phase I trial of HG-CT-1 is a dose-escalation study assessing safety and tolerability in patients with relapsed or refractory AML, a highly aggressive blood cancer with limited treatment options. Safety data from the first three patients will be submitted to an independent Data Safety Monitoring Board, which will determine whether the trial can progress to higher dose levels.

In addition to safety, the study will track several key secondary endpoints, including response rates, overall survival, progression-free survival, and the durability of response. These measures will be critical in determining the long-term clinical impact of HG-CT-1.

Dr Vladislav Sandler, chief executive of Hemogenyx, said: “The successful treatment of the third patient marks another important milestone for Hemogenyx Pharmaceuticals and for patients battling relapsed or refractory AML. We are encouraged by the favourable safety profile observed to date, together with the early signals of efficacy.”

Hemogenyx shares have surged in recent weeks. Earlier this month, the stock rallied after the company announced a manufacturing partnership to advance HG-CT-1.